Table 2 Change in Monthly Migraine Days During 12 Weeks by Age and Sex
Age | 18–45 | > 45 | ||||
|---|---|---|---|---|---|---|
Placebo | Quarterly fremanezumab | Monthly fremanezumab | Placebo | Quarterly fremanezumab | Monthly fremanezumab | |
Male | (n = 18) | (n = 18) | (n = 20) | (n = 28) | (n = 29) | (n = 25) |
LSM (SE) change from baseline, days | − 0.6 (1.16) | − 4.7 (1.41) | − 5.7 (1.26) | − 0.1 (1.07) | − 3.9 (1.05) | − 3.6 (1.14) |
P value vs placebo | 0.010 | 0.002 | 0.007 | 0.006 | ||
Female | (n = 102) | (n = 107) | (n = 108) | (n = 130) | (n = 122) | (n = 130) |
LSM (SE) change from baseline, days | − 0.5 (0.47) | − 3.5 (0.49) | − 4.0 (0.50) | − 0.7 (0.51) | − 3.9 (0.53) | − 4.1 (0.49) |
P value vs placebo | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||